Therakos, based in the United States, is a leading provider of innovative medical technologies for the treatment of various immune-mediated diseases. Founded in 1976, the company has continuously developed groundbreaking products that have significantly impacted the field of immunotherapy. The headquarters of Therakos is located in Raritan, New Jersey.

From this central location, the company manages its global operations, collaborating with healthcare professionals and patients to improve treatment options and outcomes. Therakos's primary product is the UVADEX® system, which is used in the extracorporeal photopheresis (ECP) procedure. ECP involves irradiation of white blood cells with ultraviolet A (UVA) light after their separation from the patient's blood.

This process treats diseases such as cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease (GVHD). The UVADEX® system provides a safe and efficient platform for performing ECP, offering therapeutic benefits to patients worldwide. On a global scale, Therakos has established a strong presence with subsidiaries and partnerships in various countries.

Noteworthy subsidiaries include Therakos, Ltd. Moreover, the company has formed strategic alliances and joint ventures with leading medical technology companies, expanding its reach and influence in the industry. In terms of market position, Therakos enjoys a competitive advantage due to its pioneering therapies and cutting-edge technology.

The company has gained substantial global sales and is recognized as an industry leader. It continuously strives to innovate and improve its products to maintain its position and meet the evolving needs of patients and healthcare providers. Therakos has achieved several important milestones throughout its history.

In recent years, it has expanded its product lineup to include advanced light technology devices and launched efficient delivery systems. These strategic moves have bolstered the company's growth and solidified its position in the market. As of the latest update, Therakos continues to be at the forefront of immunotherapy, providing critical solutions for patients in need.

It remains dedicated to advancing medical technologies and therapies, focusing on improving patient outcomes and expanding access to innovative treatments worldwide